PE20091851A1 - Androgeno y modulador del receptor de androgeno - Google Patents

Androgeno y modulador del receptor de androgeno

Info

Publication number
PE20091851A1
PE20091851A1 PE2009000688A PE2009000688A PE20091851A1 PE 20091851 A1 PE20091851 A1 PE 20091851A1 PE 2009000688 A PE2009000688 A PE 2009000688A PE 2009000688 A PE2009000688 A PE 2009000688A PE 20091851 A1 PE20091851 A1 PE 20091851A1
Authority
PE
Peru
Prior art keywords
androgen
receptor modulator
heart failure
androgen receptor
testosterone
Prior art date
Application number
PE2009000688A
Other languages
English (en)
Inventor
Roger Karam
Giuseppe Massimo Claudio Rosano
Maurizio Volterrani
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of PE20091851A1 publication Critical patent/PE20091851A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

REFERIDA A UNA COMBINACION FARMACEUTICA DE UN ANDROGENO TAL COMO TESTOSTERONA Y UN MODULADOR SELECTIVO DEL RECEPTOR DE ANDROGENO, LA CUAL ES UTIL EN EL TRATAMIENTO DE LA INSUFICIENCIA CARDIACA O PARA RETARDAR EL AVANCE DE LA INSUFICIENCIA CARDIACA EN MUJERES
PE2009000688A 2008-05-19 2009-05-15 Androgeno y modulador del receptor de androgeno PE20091851A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7181008P 2008-05-19 2008-05-19
US7181108P 2008-05-19 2008-05-19
US12/465,467 US20090285893A1 (en) 2008-05-19 2009-05-13 Treatment of heart failure in women

Publications (1)

Publication Number Publication Date
PE20091851A1 true PE20091851A1 (es) 2010-01-04

Family

ID=40941462

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000688A PE20091851A1 (es) 2008-05-19 2009-05-15 Androgeno y modulador del receptor de androgeno

Country Status (6)

Country Link
US (1) US20090285893A1 (es)
AR (1) AR071824A1 (es)
CL (1) CL2009001221A1 (es)
PE (1) PE20091851A1 (es)
TW (1) TW200950785A (es)
WO (1) WO2009142699A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2506838A1 (en) * 2009-12-01 2012-10-10 Noven Pharmaceuticals, INC. Transdermal testosterone device and delivery
CA2854164C (en) * 2011-11-04 2021-04-13 Agile Therapeutics, Inc. Dermal delivery compositions and methods

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5110810A (en) * 1991-02-08 1992-05-05 Virginia Commonwealth University Method of using dehydroepiandrosterone and dehydroepiandrosterone-sulfate as inhibitors of platelet aggregation
DE4312034A1 (de) * 1993-04-13 1994-10-20 Hesch Rolf Dieter Prof Dr Med Neuartige Androgene und Anabolika
US5460820B1 (en) * 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
US6395744B1 (en) * 1994-04-22 2002-05-28 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
US5780050A (en) * 1995-07-20 1998-07-14 Theratech, Inc. Drug delivery compositions for improved stability of steroids
US5883086A (en) * 1997-05-02 1999-03-16 Craft; John C. DHEA-containing nutritional supplement
US6228581B1 (en) * 1997-07-10 2001-05-08 Millennium Pharmaceuticals, Inc. Human intronic and polymorphic SR-BI nucleic acids and uses therefor
AU8779898A (en) * 1997-08-11 1999-03-01 Weider Nutrition International, Inc. Compositions and treatments to reduce side effects of administration of androgenic testosterone precursors
US20040063719A1 (en) * 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists
US20020061869A1 (en) * 1998-11-24 2002-05-23 Lichten Edward M. Free insulin testosterone test
NZ516502A (en) * 1999-06-11 2004-03-26 Watson Pharmaceuticals Inc Administration of non-oral androgenic steroids to women having an elevated level of sex hormone binding globulin (SHBG)
US6562370B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6743448B2 (en) * 2000-12-11 2004-06-01 Abraham H. Kryger Topical testosterone formulations and associated methods
US20020107230A1 (en) * 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
WO2002085297A2 (en) * 2001-04-24 2002-10-31 East Carolina University Compositions & formulations with a non-glucocorticoid steroid &/or a ubiquinone & kit for treatment of respiratory & lung disease
US20030027804A1 (en) * 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US20030175329A1 (en) * 2001-10-04 2003-09-18 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
EP1402924B1 (de) * 2002-09-04 2008-12-31 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verwendung eines Mittel zur Therapie der Herzhypertrophie
US20050100608A1 (en) * 2003-02-21 2005-05-12 Watson Pharmaceuticals, Inc. Testosterone oral dosage formulations and associated methods
TWI383993B (zh) * 2004-01-07 2013-02-01 Endorech Inc 螺旋１２取向性醫藥品
WO2005124364A1 (en) * 2004-06-15 2005-12-29 F. Hoffmann-La Roche Ag The use of cardiac hormones for diagnosing the risk of suffering from a cardiovascular complication as a consequence of cardiotoxic medication
US20060004076A1 (en) * 2004-06-30 2006-01-05 Inflabloc Pharmaceuticals, Inc. Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation
US20060258628A1 (en) * 2004-07-20 2006-11-16 Steiner Mitchell S Compositions comprising 5-alpha reductase inhibitors, and SARMs and methods of use thereof
EP1634583A1 (en) * 2004-09-09 2006-03-15 Laboratoires Besins International Testosterone gels comprising propylene glycol as penetration enhancer
CA2604400A1 (en) * 2005-04-12 2006-10-19 Unimed Pharmaceuticals, Inc. Method of treating or preventing bone deterioration or osteoporosis
JP2008536851A (ja) * 2005-04-13 2008-09-11 ユニメド ファーマスーティカルズ インク 女性でテストステロンおよび関連ステロイドの濃度を増加させる方法
US20080045486A1 (en) * 2006-08-17 2008-02-21 Tang-Liu Diane D S Ocular administration of testosterone

Also Published As

Publication number Publication date
CL2009001221A1 (es) 2009-11-27
WO2009142699A1 (en) 2009-11-26
TW200950785A (en) 2009-12-16
US20090285893A1 (en) 2009-11-19
AR071824A1 (es) 2010-07-14

Similar Documents

Publication Publication Date Title
CL2012002037A1 (es) Uso de agonista doble del glucagon-glp-1 como agente inotropico en el tratamiento de la cardiopatía o la disfuncion cardiaca
PE20150722A1 (es) Moduladores de la expresion de receptores androgenicos que comprenden un oligonucleotido modificado
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
CR20160032A (es) Compuestos de pirimidinodiona contra estados cardíacos
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
PE20150200A1 (es) Formulacion de anticuerpos
BR112012020558A2 (pt) moduladores do receptor de androgênio e seus usos
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
PE20150631A1 (es) Formas cristalinas de un modulador del receptor androgenico
PE20181523A1 (es) Tratamiento de lupus nefritis usando laquinimod
CR20110029A (es) Moduladores de diamino-piridina, pirimidina, y piridazina del receptor h4 de histamina
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CL2018001108A1 (es) Composiciones y métodos para transducción de tumores
AR077739A1 (es) Tapones lagrimales
GT201300047A (es) Tratamiento de hipertension y/o prevencion o tratamiento de insuficiencia cardiaca en un mamifero que recibe terapia anti-coagulante
CR11600A (es) Derivados de indazol
CO6351779A2 (es) Inhibidores de molecula pequeña de la activacion n-terminal del receptor de androgenos
HN2010000655A (es) Benzotiazoles como moduladores del receptor de grelina
PE20141584A1 (es) Uso de un inhibidor de aromatasa para el tratamiento del hipogonadismo y enfermedades relacionadas
MX349854B (es) Composiciones antitranspirantes y metodo para reducir la transpiracion.
CO6731081A2 (es) Método para producir y usar un copolímero de carboximetilcelulosa sódica y gosipol
TR201900240T4 (tr) Gece idrara çıkışları azaltmak için desmopresin.
AR077309A1 (es) Celulas derivadas del tejido cardiaco
PE20091851A1 (es) Androgeno y modulador del receptor de androgeno
DOP2010000156A (es) Oxazolidinonas para el tratamiento y/o profilaxis de la insuficiencia cardiaca

Legal Events

Date Code Title Description
FA Abandonment or withdrawal